Mathilde Cabart
Overview
Explore the profile of Mathilde Cabart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Greilsamer C, Campion L, Cabart M, Gourmelon C, Senellart H, Bennouna J
Bull Cancer
. 2018 Oct;
105(10):896-906.
PMID: 30348261
Introduction: Early phase therapeutic trials in oncology are being offered to an increasing number of patients. The objective of this study is to retrospectively evaluate the treatment efficacy and survival...
12.
Raimbourg J, Joalland M, Cabart M, de Plater L, Bouquet F, Savina A, et al.
Mol Cancer Ther
. 2017 May;
16(8):1634-1644.
PMID: 28522592
The benefit of EGFR-TKI in non-small cell lung cancer has been demonstrated in mutant EGFR tumors as first-line treatment but the benefit in wild-type EGFR tumors is marginal as well...
13.
Cabart M, Frenel J, Campion L, Ramee J, Dupuis O, Senellart H, et al.
Clin Colorectal Cancer
. 2016 Jun;
15(4):e165-e174.
PMID: 27256668
Introduction: There is no predictive factor of response to bevacizumab in metastatic colorectal cancer. Nevertheless, preclinical studies demonstrated an interaction between primary tumor and metastatic sites for the neoangiogenesis regulation....
14.
Cabart M, Frenel J, Campion L, Ramee J, Dupuis O, Senellart H, et al.
Bull Cancer
. 2016 May;
103(6):541-51.
PMID: 27155924
Introduction: The identification of RAS status (KRAS and NRAS) has changed the management of metastatic colorectal cancer (mCRC). The impact of the RAS mutation on cytotoxic chemotherapy efficacy has not...